Previous 10 | Next 10 |
2023-08-16 17:08:23 ET Summary Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizophrenia and Alzheimer's-related psychosis. Karuna Therapeutics faced a net loss of $103.2M in Q2 2023...
2023-08-05 05:02:06 ET Karuna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Conference Call Aug 3, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Director of Investor Relations William Meury - President and Chief Executive Officer Troy Ignelzi - Chief Fi...
2023-08-03 07:30:27 ET Karuna Therapeutics press release ( NASDAQ: KRTX ): Q2 GAAP EPS of -$2.75 beats by $0.09 . Announced the appointment of Jonathan Rosin to Chief Human Resources Officer and the promotion of Jason Brown to Chief Financial Office...
On track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. FDA in the third quarter of 2023, with a product launch in the second half of 2024, assuming approval Initiated the Phase 3 ADEPT-3 open label extension trial in the third quarter of 2023, and on track ...
Jonathan Rosin appointed to Chief Human Resources Officer Jason Brown promoted to Chief Financial Officer Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric...
2023-08-02 13:11:10 ET Karuna Therapeutics ( NASDAQ: KRTX ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$2.78 (-28.1% Y/Y) and the consensus Revenue Estimate is $0.45M (-91.5% Y/Y). Over the l...
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, August 3, 20...
2023-06-06 07:35:31 ET Summary Karuna Therapeutics' KarXT for schizophrenia is a much-hyped asset. However, there are small signs of trouble - probably nothing, but they are there. The current price seems to have priced in all these major pros and minor cons. Karuna ...
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the Goldman Sachs 44 th Annual Global Heal...
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating Ka...
News, Short Squeeze, Breakout and More Instantly...
Karuna Therapeutics Inc. Company Name:
KRTX Stock Symbol:
NYSE Market:
Karuna Therapeutics Inc. Website:
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 51.9% to $0.1549 on volume of 312,863,578 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.4% to $3.51 on volume of 229,852,079 shares SoundHound AI Inc. (SOUN) fell 3.2% to $8.37 on volu...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...